Filing Analysis
Spero Therapeutics entered into a new At-The-Market (ATM) equity offering agreement with Jefferies LLC, allowing for the sale of up to $100 million in securities. Simultaneously, the company terminated its previous ATM agreement with Cantor Fitzgerald.
🚩 Red Flags
- Potential for significant shareholder dilution through the $100M ATM offering.
- The use of an ATM offering often indicates a need for immediate liquidity to fund operations.
📋 Key Facts
- Entered into an Open Market Sale Agreement with Jefferies LLC on August 28, 2026.
- The agreement allows for the sale of up to $100,000,000 in securities (common stock, preferred stock, warrants, etc.) via an 'at-the-market' offering.
- Jefferies will receive a compensation of up to 3.0% of the aggregate gross proceeds.
- The company terminated its existing Cantor Sales Agreement with Cantor Fitzgerald effective August 28, 2026.
- No shares were sold under the Cantor agreement during the fiscal years 2024 or 2025.
Spero Therapeutics, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2026. The filing serves as a formal announcement of quarterly earnings via a press release.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2026.
- Announcement date: August 12, 2026.
- The company issued a press release (Exhibit 99.1) containing the results of operations and financial condition.
Spero Therapeutics entered into a major license agreement with Innovent Biologics for the development of SP001 (a CD40L monoclonal antibody) and simultaneously executed complex royalty financing agreements involving $105 million in senior secured notes. The filing details significant upfront, milestone, and royalty obligations to Innovent, alongside the securitization of GSK-related proceeds.
🚩 Red Flags
- High contingent liabilities: Up to $1.05 billion in potential milestone payments to Innovent.
- Complex financing structure: Use of special purpose vehicles (Holdings/Issuer) and non-recourse notes secured by future royalty streams (GSK proceeds).
- Significant upfront cash outflow ($35M) for the new license agreement.
📋 Key Facts
- Entered into an exclusive license agreement with Innovent Biologics for SP001 (CD40L monoclonal antibody) on July 8, 2026.
- Innovent Agreement terms: $35.0 million upfront payment and up to $1.05 billion in aggregate milestone payments.
- Royalty obligations to Innovent range from high single-digit to mid-teen-digit percentages on annual net sales.
- Spero issued $105,000,000 in senior secured notes via a non-recourse Note Purchase Agreement (NPA) with Healthcare Royalty Management affiliates.
- The NPA/RPA structure involves the transfer of rights to GSK proceeds (from an existing GSK agreement) as collateral and payment source.
- Spero expects to advance SP001 into Phase 2 trials for IgG4-related disease in Q2 2027.
Spero Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 23, 2026, where shareholders approved several key items including a new stock incentive plan and an amendment to increase authorized shares.
🚩 Red Flags
- Significant increase in authorized share count (doubled from 120M to 240M) which can lead to future dilution for existing shareholders.
📋 Key Facts
- Stockholders approved the Spero Therapeutics, Inc. 2026 Stock Incentive Plan, allowing for the issuance of up to 12,895,866 shares of common stock.
- Shareholders approved an amendment to the Certificate of Incorporation to increase authorized common stock from 120,000,000 to 240,000,000 shares.
- Two directors (Milind Deshpande and Kathleen Tregonay) were reelected to Class III director positions until 2029.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2026.
- The advisory vote on executive compensation was approved.
- Quorum was present at approximately 70.91% of outstanding shares.
Spero Therapeutics announced that the FDA has approved Utebzi (tebipenem pivoxil), an oral antibiotic for treating complicated urinary tract infections (cUTIs). This represents a significant regulatory milestone and commercialization catalyst for the company's lead asset.
📋 Key Facts
- FDA approval granted on June 17, 2026, for Utebzi (tebipenem pivoxil).
- Indication: Treatment of cUTIs, including pyelonephritis, in adult patients with limited/no alternative oral treatment options.
- Utebzi is the first and only oral carbapenem antibiotic approved for this patient population.
- Approval was received ahead of the PDUFA date of June 18, 2026.
- The product development and global licensing agreement (excluding select Asian territories) is with GSK.
Spero Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the filing.
🚩 Red Flags
- Concentration of executive authority: Esther Rajavelu holds three major C-suite roles (CEO, CFO, and CBO) simultaneously, which may present governance risks.
📋 Key Facts
- Reported Q1 2026 financial results on May 13, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- Esther Rajavelu is currently serving as the Chief Executive Officer, Chief Financial Officer, and Chief Business Officer.
Spero Therapeutics, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The filing serves as a standard periodic update on the company's operations and financial condition.
🚩 Red Flags
- Concentration of executive authority: Esther Rajavelu holds the positions of CEO, CFO, and CBO simultaneously, which may indicate lean staffing or potential governance risks in a public company.
📋 Key Facts
- Reported financial results for the fourth quarter and fiscal year ended December 31, 2025.
- The announcement was made via a press release dated March 26, 2026, furnished as Exhibit 99.1.
- Esther Rajavelu is currently serving in the combined roles of Chief Executive Officer, Chief Financial Officer, and Chief Business Officer.
Spero Therapeutics announced the resignation of Dr. Ankit Mahadevia from all officer and director positions, effective January 30, 2026. Additionally, the company reported that the SEC has concluded its investigation without recommending enforcement action at this time.
🚩 Red Flags
- Departure of a key officer/director (though mitigated by the consulting agreement and lack of dispute).
📋 Key Facts
- Dr. Ankit Mahadevia resigned from the Board, Development Committee, and all officer/director positions on January 30, 2026.
- The resignation is due to other professional commitments and not a dispute with the company.
- The Company and Dr. Mahadevia intend to enter into a consulting agreement for management support.
- On January 20, 2026, the SEC notified the company that it does not intend to recommend enforcement action following its investigation.
Spero Therapeutics announced that its partner GSK has filed an NDA resubmission for tebipenem HBr for the treatment of cUTI. This milestone event triggers a $25 million payment to Spero, expected in Q1 2026.
🚩 Red Flags
- The company's forward-looking statements explicitly mention 'the Company’s need for additional funding' and uncertainty regarding whether 'cash resources will be sufficient to fund its continuing operations,' indicating potential liquidity concerns despite the upcoming milestone.
📋 Key Facts
- GSK (GlaxoSmithKline Intellectual Property (No. 3) Limited) filed an NDA resubmission for tebipenem HBr with the FDA on December 19, 2025.
- The drug is an investigational oral carbapenem antibiotic for complicated urinary tract infections (cUTI), including pyelonephritis.
- A $25 million milestone payment is triggered by this NDA resubmission.
- The $25 million cash inflow is expected to be received in the first quarter of 2026.
Spero Therapeutics, Inc. filed an 8-K to announce its third quarter financial results for the period ended September 30, 2025 and provided an updated investor presentation.
📋 Key Facts
- Company announced Q3 2025 financial results on November 13, 2025.
- Released a corporate investor presentation providing business and operational updates.
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Investor Presentation).
Spero Therapeutics, Inc. filed an 8-K to announce its third quarter financial results for the period ended June 30, 2025 and provided an updated investor presentation.
📋 Key Facts
- Announced Q3 2025 financial results (period ended June 30, 2025).
- Released a corporate investor presentation containing business and operational updates.
- Filed under Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD Disclosure).
Spero Therapeutics held its 2025 Annual Meeting of Stockholders on June 12, 2025. The meeting resulted in the reelection of three directors, ratification of PricewaterhouseCoopers LLP as independent auditors, and approval of executive compensation and an amendment to the 2017 Stock Incentive Plan.
📋 Key Facts
- Annual Meeting held on June 12, 2025; quorum reached at 71.57% (40,015,633 shares).
- Stockholders approved an amendment to the 2017 Stock Incentive Plan to increase authorized shares by 3,000,000.
- Frank E. Thomas, Patrick Vink, M.D., and Esther Rajavelu were reelected to the Board of Directors (Class II) until 2028.
- PricewaterhouseCoopers LLP was ratified as independent auditors for fiscal year ending Dec 31, 2025.
- Advisory vote on executive compensation was approved.
Spero Therapeutics announced that its pivotal Phase 3 PIVOT-PO trial for tebipenem HBr met its primary endpoint and will stop early due to efficacy. The trial demonstrated non-inferiority compared to intravenous imipenem-cilastatin in treating complicated urinary tract infections (cUTIs).
📋 Key Facts
- Phase 3 PIVOT-PO trial met the primary endpoint of non-inferiority for tebipenem HBr vs. intravenous imipenem-cilastatin.
- The decision to stop early for efficacy follows a recommendation from an Independent Data Monitoring Committee (IDMC) after interim analysis of 1,690 patients.
- Primary endpoint was overall response (clinical cure plus microbiological eradication) at the test-of-cure visit.
- Safety profile remained consistent with previous studies; most common adverse events were diarrhea and headache.
- GSK plans to include this data in a regulatory filing in the second half of 2025.
Spero Therapeutics, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025. The filing serves as a formal notification that a press release containing these results was issued on May 13, 2025.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2025.
- Filing date: May 13, 2025.
- The filing includes a press release as Exhibit 99.1 regarding results of operations and financial condition.
Spero Therapeutics announced a leadership transition effective May 2, 2025, involving the appointment of Esther Rajavelu as permanent President and CEO and the mutual separation of Satyavrat Shukla from his roles as CEO and Board member.
🚩 Red Flags
- Consolidation of roles: The incoming CEO will also retain the CFO and Treasurer positions, which can create internal control complexities in micro-cap environments.
- Significant cash outflow for separation: The company is committing to substantial severance/salary continuation payments totaling over $1.3M for the outgoing CEO.
📋 Key Facts
- Esther Rajavelu to become President and CEO effective May 2, 2025; she will also continue as CFO and Treasurer.
- Ms. Rajavelu's new compensation includes a $620,000 annual base salary and 185,000 RSUs vesting over four years.
- Satyavrat Shukla is separating from the Company and Board effective May 2, 2025; separation was mutual and not due to disagreements.
- Shukla's separation package includes 12 months of salary continuation ($615,825), a pro-rated 2025 bonus ($307,913), and partial retention bonus payment ($452,813).
- The transition involves the current CFO (Rajavelu) moving into the CEO role, consolidating several executive functions.
Spero Therapeutics, Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2024.
📋 Key Facts
- Report date: March 27, 2025
- Reporting period: Fourth quarter and full year ended December 31, 2024
- The filing includes a press release as Exhibit 99.1 containing the financial results.
Spero Therapeutics received a deficiency letter from Nasdaq because its common stock closed below the $1.00 minimum bid price requirement for 30 consecutive trading days. The company has until August 25, 2025, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice/Non-compliance with minimum bid price requirement
- Potential for mandatory reverse stock split to regain compliance
- Risk of delisting from the Nasdaq Global Select Market
📋 Key Facts
- Received deficiency letter from Nasdaq on February 25, 2025.
- Violation of Nasdaq Listing Rule 5450(a)(1) regarding the $1.00 minimum bid price requirement.
- Compliance deadline is August 25, 2025.
- To regain compliance via a secondary 180-day period, the company may need to transfer listing to Nasdaq Capital Market and potentially execute a reverse stock split.
Spero Therapeutics received a Wells Notice from the SEC regarding potential violations of federal securities laws related to 2022 disclosures about tebipenem HBr. Consequently, the CEO has been placed on administrative leave and an interim leadership structure has been implemented.
🚩 Red Flags
- SEC Wells Notice (preliminary determination of wrongdoing).
- CEO placed on administrative leave pending investigation.
- Targeted investigations into former CEO and current President/CEO regarding potential securities law violations.
- Potential for officer/director bars against key leadership.
📋 Key Facts
- Received a Wells Notice from the SEC staff (Boston Regional Office) regarding preliminary determinations of civil enforcement actions.
- Investigation concerns public disclosures made between March 31, 2022, and May 3, 2022, regarding the cessation of tebipenem HBr commercialization.
- CEO Satyavrat 'Sath' Shukla has been placed on paid administrative leave effective January 7, 2025.
- Esther Rajavelu (CFO/CBO) appointed as Interim President and CEO; Frank Thomas appointed Chairman of the Board.
- Company reports ~$52.9 million in cash/equivalents as of Dec 31, 2024, with runway extending into mid-2026 via existing cash and GSK milestone payments.
- Potential SEC penalties include injunctions, civil monetary penalties, disgorgement, or officer/director bars for individuals.
Spero Therapeutics, Inc. filed an 8-K to announce its financial results for the third quarter ended September 30, 2024. The filing serves as a formal announcement of quarterly earnings via a press release.
📋 Key Facts
- Reporting period: Third Quarter ended September 30, 2024.
- Filing date: November 14, 2024.
- The company issued a press release (Exhibit 99.1) containing the results of operations and financial condition.
Spero Therapeutics announced a significant strategic restructuring involving a 39% reduction in workforce to refocus on its lead candidate, tebipenem HBr. While the company reports a cash runway extending into mid-2026, the massive headcount reduction and restructuring charges indicate a pivot toward capital preservation.
🚩 Red Flags
- Significant workforce reduction (39%) often indicates distress or a desperate need to extend runway.
- Restructuring activities are being conducted alongside clinical development, increasing execution risk.
- The company is relying on preliminary financial data that has not been audited by PwC.
📋 Key Facts
- Workforce reduction of approximately 39% announced on October 29, 2024.
- Estimated $1.1 million in cash expenditures for restructuring/severance charges.
- Reported cash and cash equivalents of ~$76.3 million as of September 30, 2024.
- Management expects current cash to fund operations into mid-2026.
- Strategic pivot focuses resources on tebipenem HBr and specific R&D efforts.
Spero Therapeutics, Inc. has updated its corporate investor presentation as of September 9, 2024. This filing is a routine disclosure intended for use in investor communications and conferences.
📋 Key Facts
- The company updated its Investor Presentation on September 9, 2024.
- The presentation is available on the company's website under the 'Investor Relations' section.
- The filing was signed by Esther Rajavelu, CFO and Chief Business Officer.
Spero Therapeutics, Inc. filed an 8-K to announce its second quarter 2024 financial results and release a corporate investor presentation.
📋 Key Facts
- Report date: August 5, 2024.
- Announced Q2 2024 results (ended June 30, 2024) via press release (Exhibit 99.1).
- Released a corporate investor presentation providing business and operational updates (Exhibit 99.2).
Spero Therapeutics, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on May 29, 2024. The meeting included the reelection of three directors and the approval of an amendment to the company's 2017 Stock Incentive Plan.
📋 Key Facts
- Stockholders approved an amendment to the 2017 Stock Incentive Plan to increase authorized shares by 3,000,000 shares.
- Quorum of 68.23% (36,772,282 shares) was present at the meeting.
- Scott Jackson, John C. Pottage, Jr., and Cynthia Smith were reelected to the Board of Directors.
- PricewaterhouseCoopers LLP was ratified as the independent auditor for fiscal year 2024.
- Advisory vote on executive compensation was approved.
Spero Therapeutics, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal mechanism to furnish quarterly earnings information via a press release.
📋 Key Facts
- Reporting period: First quarter ended March 31, 2024.
- Filing date: May 15, 2024.
- The filing includes Exhibit 99.1 containing the full press release of results.
Spero Therapeutics, Inc. announced the scheduling of its 2024 Annual Meeting of Stockholders to be held virtually on May 29, 2024.
📋 Key Facts
- The 2024 Annual Meeting of Stockholders is scheduled for May 29, 2024.
- The meeting will be conducted entirely online.
- Notice is provided in accordance with Section 1.10(b) of the Company's Amended and Restated Bylaws.
Spero Therapeutics, Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2023. The filing serves as a formal announcement of earnings rather than a specific material event like a merger or bankruptcy.
📋 Key Facts
- Reported date: March 13, 2024
- Reporting period: Fourth quarter and full year ended December 31, 2023
- The filing includes the results of operations and financial condition via a press release (Exhibit 99.1)
Spero Therapeutics, Inc. announced that Tamara Joseph will step down as Chief Legal Officer and Corporate Secretary effective March 6, 2024. The departure is characterized as pursuing other interests.
🚩 Red Flags
- Departure of a key C-suite officer (Chief Legal Officer).
📋 Key Facts
- Tamara Joseph to depart as CLO/Corporate Secretary on March 6, 2024.
- Severance includes nine months of base salary totaling $356,298.75.
- Pro-rated cash bonus for 2024 estimated at $34,266.98, payable by March 15, 2025.
- Ms. Joseph will enter a consulting agreement starting March 6, 2024, for nine months at a rate of $395.00 per hour.
- Vesting of employee stock options and RSUs will continue during the consulting term.
Spero Therapeutics, Inc. updated its investor presentation to be used for general corporate communications and marketing purposes.
📋 Key Facts
- The company updated its Investor Presentation on January 8, 2024.
- The presentation is intended for use in general corporate presentations and via the company website.
- Information provided under Item 7.01 is 'furnished' rather than 'filed', meaning it is not subject to Section 18 liability.
Spero Therapeutics provided a corporate update and 2024 outlook, reporting preliminary cash and cash equivalents of approximately $76.3 million as of December 31, 2023. The company also provided updates on its Phase 3 clinical trial for tebipenem HBr and its projected cash runway.
🚩 Red Flags
- Preliminary financial results are unaudited and subject to material change upon year-end audit.
- Clinical trial timeline (H2 2025) implies significant capital burn required over the next ~18 months.
📋 Key Facts
- Preliminary cash and cash equivalents as of Dec 31, 2023: ~$76.3 million.
- Cash runway is expected to extend into late 2025, supported by existing cash and milestone payments from GSK.
- Phase 3 clinical trial (PIVOT-PO) for tebipenem HBr has reached 'first patient, first visit'.
- Target enrollment for PIVOT-PO is approximately 2,648 patients, with completion expected in H2 2025.
Spero Therapeutics announced the initiation of the first patient, first visit for its PIVOT-PO Phase 3 clinical trial evaluating tebipenem HBr for complicated urinary tract infections (cUTI). The filing also details significant potential milestone and royalty payments tied to a license agreement with GSK.
🚩 Red Flags
- Clinical trial risk: Success is dependent on meeting the non-inferiority margin for microbiological intention-to-treat population.
📋 Key Facts
- Initiated the PIVOT-PO Phase 3 trial, a global, randomized, double-blind study comparing oral tebipenem HBr vs. IV imipenem cilastatin.
- The trial aims to enroll approximately 2,648 patients with cUTI/AP.
- Under the GSK license agreement, Spero is entitled to $95.0 million in development milestones payable in four equal semiannual installments.
- Additional potential milestones include $25M for FDA NDA submission and up to $175M in commercial/sales-based milestones.
- Potential royalties on net sales of tebepenem HBr in most territories (excluding Japan and certain Asian countries).